FDA had ordered shut down of the plant for not treating a batch of talcum powder for ethylene oxide residue in 2007.
The division bench of Justices S J Vazifdar and K R Shriram was hearing a petition filed by Johnson and Johnson challenging the June 24 order of FDA appellate authority.
While allowing resumption of production, court today referred the matter back to the appellate authority for a reconsideration, saying that "the proportionality (of the punishment vis a vis the offence) issue needs to be seen".
FDA alleged that the company did not register the process with it, and failed to conduct tests for traces of ethylene oxide in the powder.
The company challenged the order, but in June the cancellation of license was upheld by the FDA's appellate authority.
Senior counsel Rafiq Dada, appearing for the company, said the company was not using ethylene oxide treatment process anymore.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
